Top
image credit: Unsplash

Digital tools driving innovative clinical trials

Preliminary research suggests that hybrid DCTs can reduce trial timing and resources, improve patient-centricity and patient engagement, and expand access and recruitment and increase diversity, mitigate bias, and reinforce inclusion in clinical trials. A recent Science 37 survey noted that nearly three-quarters (73%) of respondents from the pharma industry were planning a hybrid or DCT, up from 49% in 2021.

“DCTs have been around for many years, long before the pandemic, but now companies have had the opportunity to utilise DCT approaches,” John Reites, CEO of Thread, told pharmaphorum.

Read More on Pharmaphorum